Table 3.
Fold rise in antibody titres in presence and absence of maternal antibody (MT-Ab).
| Immunogen | Infants with MT-Ab | Infants without MT-Ab | ||||
|---|---|---|---|---|---|---|
| Number with ≥ 4fold rise in titers/Total Number with MT-Ab (%) | Number of infants seroconverting to protective levels/total number without MT-Ab (%) | |||||
| PT1 | PT2 | FT | PT1 | PT2 | FT | |
| Tetanus Toxoid | 2/22 (9.1) | 2/55 (3.6) | 0/54 | 0/0 | 0/0 | 0/0 |
| Diphtheria Toxoid |
18/19 (94.7) | 49/55 (89.1) | 46/54 (85.2) | 03/03 (100) | 0/0 | 0/0 |
| Hib (PRP) | 15/22 (68.2) | 41/55 (74.5) | 41/54 (75.9) | 0/0 | 0/0 | 0/0 |
| Whole cell Pertussis | 8/10 (80) | 31/39 (79.5) | 23/32 (71.9) | 9/13 (69.2) | 13/16 (81.2) | 8/33 (24) |
| Hepatitis B surface antigen | 12/13 (92.3) | 36/39 (92.4) | 33/36 (91.7) | 9/9 (100) | 11/14 (78.6) | 36/36 (100) |
Except for a small proportion of PT1 (2/22) and PT2 (2/55) infants, 4fold rise in anti-TT titers was not recorded post-immunization. It would be necessary to determine dynamics of these antibodies till boosted by an additional dose in 15th to 18th month.
MT-Ab, maternal antibody.